PRODUCT NEWS: FDA Approves Chewable Form of Dog, Cat Antibiotic

Piedmont Animal Health has recently gained FDA approval for Baytril Soft Chewable Tablets—an antibiotic prescribed for the management of diseases associated with bacteria susceptible to enrofloxacin.

Baytril, which has been on the market since 1988, was developed by Bayer Animal Health and has been used to treat a broad spectrum of bacteria that cause skin, urinary, respiratory, and other infections.

RELATED:

• WVC 2017: Dealing with Chronic Ear Infections in Dogs
• Antibiotic Selection in Pyoderma

But now, with the help of Piedmont’s soft-chew platform, the antibiotic can be administered much more easily.

“I fully expect that Piedmont’s current portfolio of proprietary drugs will significantly grow and disrupt the indication areas we are targeting,” Piedmont Founder and CEO Roland Johnson said. “This approval is yet another stepping stone toward that objective.”

Piedmont’s soft-chew platform uses meat-free cubes made without water, heat, or an extrusion process so they can be stably infused with active pharmaceutical ingredients.

This is the fourth animal drug marketed by Bayer that uses Piedmont’s soft-chew platform. Bayer acquired the exclusive rights to Piedmont’s chewable drug delivery platform in November 2010.

For full prescribing information, click here.